Eisai Sees Generics Opportunity In Japan For Innovator Companies
This article was originally published in PharmAsia News
Executive Summary
A push by the Japanese government to increase generic drug utilization is an opportunity for innovator companies to jump into the generics space following Japanese patent expiries, according to Eisai CEO Haruo Naito
You may also be interested in...
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.
Banyu’s Elizabeth Cobbs on Merck’s Regulatory Policies in Japan: An Interview with PharmAsia News (Part 2 of 2)
Banyu Pharmaceutical, a Japanese company established in 1915, after its founder discovered a remedy for syphilis, became a wholly owned subsidiary of Merck in 2004. Since then, Banyu has had a somewhat unique position in Japan as an affiliate of a global pharma company, but with strong Japanese roots. Elizabeth Cobbs, Banyu's senior director of public and industry policy, sat down with PharmAsia News' Tokyo bureau to discuss the company's strategic outlook and regulatory challenges.
Eisai Plans R&D Revamp To Turn The Development Tide
Six autonomous product creation units to focus on neuroscience, oncology, antibodies and immunological anti-inflammatory diseases, with units also focused on late stage drugs and Japanese clinical research.